Poly(amidoamine) polymers: Soluble linear amphiphilic drug-delivery systems for genes, proteins and oligonucleotides

Therapeutic Delivery

Volumn 2, Issue 7, 2011, Pages 907-917

  Pettit, Marie W ^a   Griffiths, Peter ^b   Ferruti, Paolo ^c,d   Richardson, Simon C W ^a  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

^d Consorzio Interuniversitario Nazionale per la Scienza e Tecnologia dei Materiali ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DOXORUBICIN; MACROGOL; ONCOSPAR; POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYLYSINE; PROTEIN DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

BIODEGRADABILITY; CELL NUCLEUS; CHEMICAL STRUCTURE; CYTOSOL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; GENE DELIVERY SYSTEM; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SYNTHESIS; VIRAL GENE DELIVERY SYSTEM;

EID: 79961206189     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.55     Document Type: Review

References (56)

1. Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for targeting cancer. Trends Biotech. 24(1), 39-47 (2006). (Pubitemid 43017749)
2. Fee CJ, Alstine JM. PEG-proteins: Reaction engineering and separation issues. Chem. Engin. Sci. 61(3), 924-939 (2006).
3. Duncan R. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv. Drug Del. Rev. 61(13), 1131-1148 (2009).
4. Graham MJ. Pegaspargase: a review of clinical studies. Adv. Drug Del. Rev. 55(10), 1293-1302 (2003).
5. Vasey PA, Duncan R, Kaye SB, Cassidy J. Clinical Phase 1 trail of PK1 (HPMA co-polymer doxorubicin).Eur. J. Cancer 31(6), s193 (1995).
6. Ferruti P, Ranucci E, Sartore L et al. Recent results on functional polymers and macromonomers of interest as biomaterials or for biomaterial modification. Biomaterials 15(15), 1235-1241 (1994).
7. De Souza R, Zahedi P, Allen CJ, Piquette- Miller M. Polymeric drug delivery systems for localized cancer chemotherapy. Drug Del. 17(6), 365-375 (2010).
8. Richardson S, Ferruti P, Duncan R. Poly(amidoamine)s as potential endosomolytic polymers: evaluation in vitro and body distribution in normal and tumor bearing animals. J. Drug Targeting 6(6), 391-404 (1999). (Pubitemid 29452683)
9. Wan KW, Malgesini B, Verpilio I et al. Poly(amidoamine) salt form: effect on pH dependent membrane activity and polymer conformation in solution. Biomacromolecules 5, 1102-1109 (2004). (Pubitemid 38702288)
10. Pattrick NG, Richardson SCW, Casolaro M, Ferruti P, Duncan R. Poly(amidoamines)- mediated intracytoplastic delivery of ricin A-chain and gelonin. J. Control. Rel. 77(3), 225-232 (2001). (Pubitemid 33145474)
11. Richardson SCW, Pattrick NG, Lavignac N, Ferruti P, Duncan R. Intracellular fate of bioresponsive poly(amidoamine)s in vitro and in vivo. J. Control. Release 142(1), 78-88 (2010).
12. Richardson SCW, Pattrick NG, Man SYK, Ferruti P, Duncan R. Poly(amidoamine)s as potential nonviral vectors: ability to form interpolyelectrolyte complexes and to mediate transfection in vitro. Biomacromolecules 2(3), 1023-1028 (2001). (Pubitemid 32894664)
13. Piest M, Engbersen J. Effects of charge density and hydrophobicity of poly(amidoamine)s for non-viral gene delivery. J. Control. Release 148(1), 83-90 (2010).
14. van der Aa LJ, Vader P, Storm G et al. Optimization of poly(amido amine)s as vectors for siRNA delivery. J. Control. Release 150, 177-186 (2011).
15. Malik N, Wiwattanapatapee R, Klopsch R et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J. Control. Release 65(1-2), 133-148 (2000). (Pubitemid 30122922)
16. Wiwattanapatapee R, Carreno-Gomez B, Malik N, Duncan R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharmaceut. Res. 17(8), 991-998 (2000).
17. Patri A, Majoros I, Baker J. Dendritic polymer macromolecular carriers for drug delivery. Curr. Opin. Chem. Biol. 6(4), 466-471 (2002). (Pubitemid 34804769)
18. Agrawal P, Gupta U, Jain NK. Glycoconjugated peptide dendrimers-based nanoparticle system for the delivery of chloroquine phosphate. Biomaterials 28(22), 3349-3359 (2007). (Pubitemid 46693974)
19. Heegaard PMH, Boas U, Sorensen NS. Dendrimers for vaccine and immunostimulatory uses, a review. Bioconjugate Chem. 21(3), 405-418 (2010).
20. Tomalia D. Birth of a new macromolecular architecture dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog. Polymer Sci. 30(3-4), 294-324 (2003). (Pubitemid 40642933)
21. Hill IRC, Garnett MC, Bignotti F, Davis SS. In vitro cytotoxicity of poly(amidoamine)s: relevance to DNA delivery. Biochim.Biophys. Acta 1427, 161-174 (1999). (Pubitemid 29182768)
22. Ferruti P, Duncan R, Richardson S. Tailor-made soluble polymer carriers. In:Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems . Gregoriadis G, McCormac B (Eds).Plenum Publishing Corporation, NY, USA 207-224 (1998).
23. Ferruti P, Marchisio AM, Barbucci R. Synthesis, physicochemical properties and biomedical applications of poly(amido-amine)s. Polymer 26(9), 1336-1348 (1984).
24. Ferruti P, Manzoni S, Richardson SCW et al. Amphoteric linear poly(amido-amine)s as endosomolytic polymers: correlation between physicochemical and biological properties. Macromolecules 33(21), 7793-7801 (2000).
25. Griffiths PC, Paul A, Khayat Z et al. Understanding the mechanism of action of poly(amidoamine)s as endosomolytic polymers: correlation of physicochemical and biological properties. Biomacromolecules 5, 1422-1427 (2004). (Pubitemid 39089745)
26. Chokaskulnimitr S, Masuda H, Tokuda Y, Takakura M, Hashida M. In vitro cytotoxicity of macromolecules in different cell culture systems. J. Control. Rel. 34, 233-241 (1995).
27. Griffiths PC, Khayat Z, Tse S, Heenan RK, King SM, Duncan R. Studies on the mechanism of interaction of a bioresponsive endosomolytic polyamidoamine with interfaces. 1. Micelles as model surfaces. Biomacromolecules 8, 1004-1012 (2007). (Pubitemid 46488485)
28. Khayat Z, Griffiths P, Grilo I, Heenan R, King S, Duncan R. Characterizing the size and shape of polyamidoamines in solution as a function of pH using neutron scattering and pulsed-gradient spin-echo NMR. Int. J. Pharma. 317(2), 175-186 (2006).
29. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Del. Rev. 55(10), 1261-1277 (2003). (Pubitemid 37464561)
30. Nishikawa M, Takakura Y, Hashida M. Pharmacokinetic considerations regarding non-viral cancer gene therapy. Cancer Sci. 99(5), 856-862 (2008). (Pubitemid 351997585)
31. Rackstraw BJ, Stolnik S, Davis SS, Bignotti F, Garnett MC. Development of multicomponent DNA delivery systems based upon poly(amidoamine) - PEG co-polymers. Biochem. Biophys. Acta 1576(3), 269-286 (2002). (Pubitemid 34655770)
32. Dash PR, Read ML, Fisher KD et al. Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin. J. Biol. Chem. 275, 3793-3802 (2000). (Pubitemid 30094601)
33. Richardson SCW, Wallom KL, Ferguson EL et al. The use of fluorescence microscopy to define polymer localization to the late endocytic compartments in cells that are targets for drug delivery. J. Control. Release 127(1), 1-11 (2008).
34. Seib FP, Jones AT, Duncan R. Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16F10 melanoma cells. J. Control. Release 117(3), 291-300 (2007). (Pubitemid 46216575)
35. Wang LH, Rothberg KG, Anderson RG. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J. Cell Biol. 123(5), 1107-1117 (1993). (Pubitemid 23352421)
36. Jones N, Hill IRC, Stolnik S, Bignotti F, Davis S, Garnett M. Polymer chemical structure is a key determinant of physicochemical and colloidal properties of polymer-DNA complexes for gene delivery. Biochim. Biophys. Acta 1517, 1-18 (2000).
37. Richardson SCW, Kolbe HVJ, Duncan R. Potential of low molecular mass chitosan on a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Intl J. Pharmaceutics 178(2), 231-243 (1999). (Pubitemid 29078577)
38. Dyer PDR, Richardson SCW. Delivery of biologics to select organelles - the role of biologically active polymers. Expert Opin. Drug Deliv. 8(4), 403-407 (2011).
39. Boussif O, Lezoualc'h F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethyleneimine. Proc. Natl Acad. Sci. USA 92(16), 7297-7301 (2005).
40. Won Y, Sharma R, Konieczny S. Missing pieces in understanding the intracellular trafficking of polycation/DNA complexes. J. Control. Release 139(2), 88-93 (2009).
41. Lavignac N, Lazenby M, Foka P et al. Synthesis and endosomolytic properties of poly(amidoamine) block copolymers. Macromol. Biosci. 4(10), 922-929 (2004). (Pubitemid 39524167)
42. Heilbronn R, Weger S. Viral vectors for gene transfer: current status of gene therapeutics. Handb. Exp. Pharmacol. 197, 143-170 (2010).
43. Pichon C, Billiet L, Midoux P. Chemical vectors for gene delivery: uptake and intracellular trafficking. Curr. Opin. Biotechnol. 21(5), 640-645 (2010).
44. Kabanov AV, Kabanov VA. DNA complexes with polycations for the delivery of genetic material into cells. Bioconjugate Chem. 6, 7-20 (1995).
45. Slita AV, Kasyanenko NA, Nazorova OV et al. DNA-polycation complexes. Effect of polycation structure on physico-chemical and biological properties. J. Biotechnol. 127, 679-693 (2007). (Pubitemid 44959107)
46. Jeong JH, Kim S, Park TG. Molecular design of functional polymers for gene therapy. Prog. Polymer Sci. 32(11), 1239-1274 (2007). (Pubitemid 47513188)
47. Ou M, Xu R, Kim SH, Bull D, Kim SW. A family of bioreducible poly(disulphide amine)s for gene delivery. Biomaterials 30(29), 5804-5814 (2009).
48. Gruenberg J. The endocytic pathway: a mosaic of domains. Nat. Rev. Mol. Cell Biol. 2(10), 721-730 (2001). (Pubitemid 33679834)
49. Eden ER, White IJ, Futter CE. Down-regulation of epidermal growth factor receptor signaling within multivesicular bodies. Biochem. Soc. Trans. 37(1),173-177 (2009).
50. Hartley MR, Lord JM. Cytotoxic ribosome-inactivating lectins from plants. Biochimica Biophysica Acta (BBA) - Proteins Proteomics 1701(1-2), 1-14 (2004). (Pubitemid 39140781)
51. Lord MJ, Jolliffe NA, Marsden CJ et al. Ricin: mechanisms of cytotoxicity. Toxicol. Rev. 22(1), 53-64 (2003). (Pubitemid 37270712)
52. Jetzt AE, Cheng J-S, Tumer NE, Cohick WS. Ricin A-chain requires c-Jun N-terminal kinase to induce apoptosis in nontransformed epithelial cells. Int. J. Biochem. Cell Biol. 41(12), 2503-2510 (2009).
53. Johnstone SR, Morrice LM, Heyningen S. The heavy chain of tetanus toxin can mediate the entry of cytotoxic gelonin into intact cells. FEBS Lett. 265 (1-2), 101-103 (1990). (Pubitemid 20189404)
54. Coue G, Feijen J, Engbersen JFJ. Development of biodegradable poly(amidoamine)s for protein delivery. J. Control. Release 132(3), e2-e3 (2008),
55. Hacein-Bey-Abina S, Hauer J, Lim A et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363(4), 355-364 (2010).
56. Loudet A, Han J, Barhoumi R, Pellois JP, Burghardt RC, Burgess K. Non-covalent delivery of proteins into mammalian cells. Org. Biomol. Chem. 6(24), 4516-4522 (2008).